[1]吕汪霞,马胜林.西妥昔单抗的临床研究新进展[J].医学综述,2010,16(9):1345-1348.DOI:10.3969/j.issn.1006-2084.2010.09.023. Lyu WX,Ma SHL.New progress of clinical research of cetuximab monoclonal antibodies[J].Med Rev,2010,16(9):1345-1348.DOI:10.3969/j.issn.1006-2084.2010.09.023. [2]中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准[J].中华放射肿瘤学杂志,2010,19(2):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. China experts group of non-surgical treatment for clinical staging of esophageal cancer. Non-surgical standards of clinical staging of esophageal cancer[J].Chin J Radiat Oncol,2010,19(2):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. [3]肖泽芬.食管癌[A]//殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].第4版.北京:中国协和医科大学出版社,2008:546-573. Xiao ZF. Esophageal cancer[A]//Yin WB,Yu ZH,Xu GZH,et al. Radiation oncology therapeutics[M].4 ed. Beijing:Publishing house of peking union medical college,2008:546-573. [4]David HI,Jennifer M,Mohan S,et al. RTOG 0436:a phase Ⅲ trial evaluating the addition of cetuximab to paclitaxel,cisplatin,and radiation for patients with esophageal cancer treated without surgery[J].J Clin Oncol,2014(Suppl;abstr 4007).DOI:10.1037/0003-066X.59.1.29. [5]Karapetis CS,Khambata FS,Jonker DJ,et al. K–ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med,2008,359(17):1757-1765.DOI:10.1056/NEJMoa0804385.
2016, Vol. 25 
